Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Buy Rating at HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright's price objective indicates a potential upside of 484.80% from the company's current price.

Several other equities analysts have also commented on the company. Wedbush raised Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. Oppenheimer reiterated an "outperform" rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL traded down $0.53 during midday trading on Friday, hitting $3.42. The company's stock had a trading volume of 1,555,206 shares, compared to its average volume of 1,329,579. The business's 50 day simple moving average is $3.41 and its 200 day simple moving average is $5.52. The company has a market cap of $243.73 million, a P/E ratio of -1.39 and a beta of 1.74. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.07.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Quarry LP acquired a new position in Zentalis Pharmaceuticals during the third quarter worth $55,000. Paloma Partners Management Co purchased a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter worth about $37,000. Erste Asset Management GmbH acquired a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at about $37,000. PDT Partners LLC increased its holdings in Zentalis Pharmaceuticals by 166.0% during the 3rd quarter. PDT Partners LLC now owns 107,159 shares of the company's stock valued at $394,000 after acquiring an additional 66,868 shares in the last quarter. Finally, Verition Fund Management LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock valued at $5,536,000 after purchasing an additional 951,500 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.